CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

Triple-negative breast cancer (TNBC) is an aggressive disease that lacks established markers to direct therapeutic intervention. Thus, these tumors are routinely treated with cytotoxic chemotherapies (e.g., anthracyclines), which can cause severe side effects that impact quality of life. Recent stud...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: McClendon, A. Kathleen, Dean, Jeffry L., Rivadeneira, Dayana B., Yu, Justine E., Reed, Christopher A., Gao, Erhe, Farber, John L., Force, Thomas, Koch, Walter J., Knudsen, Erik S.
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2012
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3409014/
https://ncbi.nlm.nih.gov/pubmed/22751436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.21127
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares